Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models.

The AAPS Journal
Camille VongMats O Karlsson

Abstract

Efficient power calculation methods have previously been suggested for Wald test-based inference in mixed-effects models but the only available alternative for Likelihood ratio test-based hypothesis testing has been to perform computer-intensive multiple simulations and re-estimations. The proposed Monte Carlo Mapped Power (MCMP) method is based on the use of the difference in individual objective function values (ΔiOFV) derived from a large dataset simulated from a full model and subsequently re-estimated with the full and reduced models. The ΔiOFV is sampled and summed (∑ΔiOFVs) for each study at each sample size of interest to study, and the percentage of ∑ΔiOFVs greater than the significance criterion is taken as the power. The power versus sample size relationship established via the MCMP method was compared to traditional assessment of model-based power for six different pharmacokinetic and pharmacodynamic models and designs. In each case, 1,000 simulated datasets were analysed with the full and reduced models. There was concordance in power between the traditional and MCMP methods such that for 90% power, the difference in required sample size was in most investigated cases less than 10%. The MCMP method was able to prov...Continue Reading

References

Jun 1, 1992·Journal of Pharmacokinetics and Biopharmaceutics·D B WhiteT H Grasela
Mar 1, 1997·Clinical Pharmacology and Therapeutics·L B Sheiner
May 29, 1998·Journal of Clinical Pharmacology·E I EtteT M Ludden
May 5, 2001·Pharmaceutical Research·P I Lee
Jul 27, 2001·Journal of Pharmacokinetics and Pharmacodynamics·U WählbyM O Karlsson
Nov 27, 2002·Journal of Pharmacokinetics and Pharmacodynamics·Ulrika WählbyMats O Karlsson
Dec 24, 2002·Clinical Pharmacology and Therapeutics·E Niclas Jonsson, Lewis B Sheiner
Mar 3, 2004·Computer Methods and Programs in Biomedicine·Marco ForacchiaAlfredo Ruggeri
Feb 11, 2005·Methods of Information in Medicine·G DahmenA Ziegler
Jul 19, 2005·Computer Methods and Programs in Biomedicine·Lars LindbomNiclas Jonsson
Nov 15, 2005·Journal of Pharmacokinetics and Pharmacodynamics·Dongwoo KangDavide Verotta
Apr 6, 2006·Journal of Biopharmaceutical Statistics·Kayode OgungbenroGordon Graham
Jun 14, 2006·Journal of Pharmacokinetics and Pharmacodynamics·Liping ZhangSandra R B Allerheiligen
Apr 12, 2007·British Journal of Clinical Pharmacology·Kristin E KarlssonE Niclas Jonsson
May 25, 2007·Clinical Pharmacology and Therapeutics·R L LalondeR Miller
May 17, 2008·European Journal of Clinical Pharmacology·Kayode Ogungbenro, Leon Aarons
Feb 19, 2009·Journal of Pharmacokinetics and Pharmacodynamics·J M McGreeS B Duffull
May 14, 2009·BMJ : British Medical Journal·Pierre CharlesPhilippe Ravaud
Dec 8, 2009·Journal of Pharmacokinetics and Pharmacodynamics·Kayode Ogungbenro, Leon Aarons
Apr 2, 2010·Journal of Biopharmaceutical Statistics·Yi Tsong, Joanne Zhang
Jul 2, 2010·Clinical Pharmacology and Therapeutics
Aug 20, 2010·Journal of Biopharmaceutical Statistics·Kayode Ogungbenro, Leon Aarons

❮ Previous
Next ❯

Citations

Jul 12, 2013·Journal of Pharmacokinetics and Pharmacodynamics·Dinko RekićUlrika S H Simonsson
Mar 5, 2016·Journal of Pharmacokinetics and Pharmacodynamics·Sebastian UeckertAndrew C Hooker
Jul 4, 2015·Clinical Pharmacokinetics·Frederique RodieuxMarc Pfister
Jul 10, 2013·CPT: Pharmacometrics & Systems Pharmacology·R J KeizerA Hooker
Jul 28, 2013·CPT: Pharmacometrics & Systems Pharmacology·K E KarlssonM O Karlsson
Jun 19, 2016·Diabetes & Metabolism·S BucherUNKNOWN representing the S. AGES investigators
Apr 9, 2017·Journal of Pharmacokinetics and Pharmacodynamics·Rasmus Vestergaard JuulTrine Meldgaard Lund
May 8, 2018·CPT: Pharmacometrics & Systems Pharmacology·Moustafa M A IbrahimMats O Karlsson
Mar 1, 2017·Antimicrobial Agents and Chemotherapy·Jesmin PermalaMartin Bergstrand
Sep 30, 2018·Basic & Clinical Pharmacology & Toxicology·Tore Bjerregaard StageMaria C Kjellsson
Jun 28, 2013·Pharmacological Reviews·Elisabet I Nielsen, Lena E Friberg
Oct 28, 2019·Journal of Pharmacokinetics and Pharmacodynamics·A BrekkanE L Plan
Sep 29, 2019·Multivariate Behavioral Research·Jason D Rights, Sonya K Sterba
Jul 16, 2015·European Journal of Clinical Pharmacology·Shuying YangSteven Pascoe
Mar 27, 2018·CPT: Pharmacometrics & Systems Pharmacology·Gustaf J WellhagenMaria C Kjellsson
Mar 5, 2021·Journal of Pharmacokinetics and Pharmacodynamics·Michiel J van Esdonk, Jasper Stevens
Feb 14, 2021·British Journal of Clinical Pharmacology·Yucheng ShengChao Chen
May 6, 2021·CPT: Pharmacometrics & Systems Pharmacology·Chao ChenMats O Karlsson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.